Anthera Pharmaceuticals Inc (ANTH)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John Craig Thompson
Employees:
21
25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD, CA 94545
(510) 856-5600

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. It develops phase 3 product candidates, which includes blisibimod and liprotamase. Anthera Pharmaceuticals was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.

Data derived from most recent annual or quarterly report
Market Cap 628.303 Thousand Shares Outstanding26.179 Million Avg 30-day Volume 60.388 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.95
Price to Revenue0.0 Debt to Equity0.0 EBITDA-22.994 Million
Price to Book Value1.5312 Operating Margin0.0 Enterprise Value275.669 Thousand
Current Ratio3.303 EPS Growth0.906 Quick Ratio3.056
1 Yr BETA 0.0707 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth39.19 Altman Z-Score-76.6878 Free Cash Flow to Firm -41.023 Million
View SEC Filings from ANTH instead.

View recent insider trading info

Anthera Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ANTH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANTH

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2018-09-12 by MCMANIGLE MARK DREW
  • 4: filed on 2018-01-09 by THOMPSON JOHN CRAIG
  • 4: filed on 2018-01-09 by SHANAHAN WILLIAM R JR
  • 4: filed on 2018-01-09 by LIU MAY
  • 4: filed on 2018-01-09 by TRUEX PAUL F
  • 4: filed on 2018-01-09 by THOMPSON DAVID E.
  • 4: filed on 2018-01-09 by SAGER PHILIP
  • 4: filed on 2018-01-09 by MUELLER BRIAN
  • 4: filed on 2018-01-09 by FURSE BRENT
  • 4: filed on 2018-01-09 by HENNEY CHRISTOPHER S

    • Events (8k)

  • 8-K: filed on 2018-05-30:
    Item 8.01: Other Events
  • 8-K: filed on 2018-05-23:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2018-04-16:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2018-03-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-03-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-25:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-09:
    Item 3.02: Unregistered Sales of Equity Securities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-11-17:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-11-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-10-25:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MCMANIGLE MARK DREW CHIEF LIQUIDATING OFFICER

    • Officer
    • Director
    		 0 2018-09-11 0

    TRUEX PAUL F

    • Director
    		 186,203 2018-01-05 0

    SHANAHAN WILLIAM R JR CHIEF MEDICAL OFFICER

    • Officer
    		 567,876 2018-01-05 0

    HENNEY CHRISTOPHER S

    • Director
    		 471,839 2018-01-05 0

    THOMPSON DAVID E.

    • Director
    		 185,435 2018-01-05 0

    THOMPSON JOHN CRAIG PRESIDENT & CEO

    • Officer
    • Director
    		 1,866,922 2018-01-05 0

    MUELLER BRIAN

    • Director
    		 179,410 2018-01-05 0

    LIU MAY PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 459,368 2018-01-05 0

    FURSE BRENT

    • Director
    		 169,410 2018-01-05 0

    SAGER PHILIP

    • Director
    		 169,410 2018-01-05 0

    DICKINSON KLARA CHIEF REGULATORY OFFICER

    • Officer
    		 56,250 2017-05-20 0

    OLSON CHARLES V CHIEF TECHNOLOGY OFFICER

    • Officer
    		 61,269 2017-05-20 0

    ENGLE STEVEN B

    • Director
    		 41,379 2016-04-27 0

    PENNINGTON JAMES INTERIM CHIEF MEDICAL OFFICER

    • Officer
    		 17,688 2016-04-01 0

    HISLOP COLIN CHIEF MEDICAL OFFICER

    • Officer
    		 31,892 2016-02-12 0

    ODINK DEBRA CHIEF TECHNOLOGY OFFICER

    • Officer
    		 21,751 2015-10-12 0

    ZWEIFACH SANFORD S

    • Director
    		 28,846 2015-05-21 0

    ZENYAKU KOGYO CO., LTD.

    • 10% Owner
    		 2,795,895 2015-01-27 0

    SPIEGELMAN DANIEL K

    • Director
    		 12,500 2014-06-13 0

    DZIURZYNSKI BOGDAN

    • Director
    		 10,000 2013-05-31 0

    HEALY JAMES

    • Director
    		 132,443 2013-05-17 0

    LOWE CHRISTOPHER P. CFO AND CHIEF BUSINESS OFFICER

    • Officer
    		 1,408,915 2013-05-17 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP IV LLC

    ISALY SAMUEL D

    • Director
    		 7,462,000 2013-01-30 0

    KILFOIL GEORGINA SVP,PRODUCT DEV.& PROJECT MGMT

    • Officer
    		 117,651 2013-01-03 0

    THOMPSON PETER A.

    • Director
    		 0 2012-05-08 0

    SOFINNOVA VENTURE PARTNERS VI L P

    SOFINNOVA MANAGEMENT VI, L.L.C.

    SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

    SOFINNOVA VENTURE AFFILIATES VI LP

    AZAN ALAIN

    POWELL MICHAEL

    BUATOIS ERIC

    • 10% Owner
    		 44,969 2011-12-30 0

    VANTAGEPOINT VENTURE ASSOCIATES IV LLC

    VANTAGEPOINT VENTURE PARTNERS IV Q LP

    VANTAGEPOINT VENTURE PARTNERS IV LP

    VANTAGEPOINT VENTURE PARTNERS IV PRINCIPALS FUND LP

    SALZMAN ALAN E

    • 10% Owner
    		 5,357,528 2011-07-07 0

    SANTEL DONALD J

    • Director
    		 0 2011-06-30 0

    BIANCHI ANNETTE

    • Director
    		 No longer subject to file 2011-04-19 0

    LEHENY A. RACHEL

    • Director
    		 0 2010-09-30 0

    TRIAS JOAQUIM SR. VP, PRECLINICAL DEVELOPMEN

    • Officer
    		 198,546 2010-09-21 0

    FRITSCH URSULA VP, GLOB. REG. & COMPLIANCE

    • Officer
    		 83,615 2010-06-30 0

    LAU STEPHEN VP, CORP. & BUSINESS DEV.

    • Officer
    		 7,000 2010-06-30 0

    SOFINNOVA VENTURE PARTNERS VI L P

    SOFINNOVA MANAGEMENT VI, L.L.C.

    SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

    SOFINNOVA VENTURE AFFILIATES VI LP

    BUATOIS ERIC

    AZAN ALAIN

    POWELL MICHAEL

    HEALY JAMES

    • Director
    • 10% Owner
    		 45,809 2010-03-04 0

    SOFINNOVA VENTURE PARTNERS VI L P

    • 10% Owner
    		 3,983,230 2010-03-04 0

    SOFINNOVA MANAGEMENT VI, L.L.C.

    • 10% Owner
    		 4,072,203 2010-03-04 0

    SOFINNOVA VENTURE PARTNERS VI L P

    SOFINNOVA MANAGEMENT VI, L.L.C.

    • 10% Owner
    		 0 2010-02-23 0

    PENNINGTON JAMES E CHIEF MEDICAL OFFICER & EX. VP

    • Officer
    		 105,140 2010-02-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 22:15:04 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 21:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 21:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 20:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 20:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 19:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 19:15:04 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 18:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 18:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 17:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 17:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 16:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 16:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 15:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 15:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 14:45:02 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 14:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 13:45:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 13:15:03 UTC -20.3209 20.3909 90000
    ANTHERA PHARMACEUTICALS INC ANTH 2021-10-15 12:45:03 UTC -20.3209 20.3909 90000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments